Oventus Medical Ltd (ASX:OVN) is pleased to announce the appointment of a Medical Technology Advisory Board of international sleep experts to help guide the development and commercialisation of the Company's Sleep Treatment Platform.
Anti-counterfeit and customer engagement solutions provider YPB Group Ltd (ASX:YPB) is pleased to announce further success with the joint "Cannabis Confirmed" initiative with the signing of an Authentication Services Agreement with Totem Vaporizers Inc., a leading vaporiser manufacturer in the cannabis industry.
Anti-counterfeit and customer engagement solutions provider YPB Group Ltd (ASX:YPB) is pleased to announce that its channel partner in the legal cannabis industry, Namaste Technologies (CVE:N), has released its recreational cannabis market strategy to the TSX Venture Exchange.
Anti-Counterfeit and Customer Engagement solutions provider YPB Group Ltd (ASX:YPB) has signed its first cannabis industry client in the USA and the second client since the launch of the partnership with Namaste Technologies (CVE:N).
YPB Group Ltd (ASX:YPB) provides the Company's Review of Q1 2018 Activities.
Anti-Counterfeit and Customer Engagement solutions provider YPB Group Ltd (ASX:YPB) has signed its first client under its partnership with Namaste Technologies (CVE:N), leading Chinese vaporizer manufacturer Kingtons.
Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 30 June 2018 (Q4 FY2018) and is pleased to provide a review of progress made during the quarter.
Anti-Counterfeit and Customer Engagement solutions company YPB Group Ltd (ASX:YPB) has signed a three year Master Supply Agreement with Namaste Technologies Inc (CVE:N) whereby the two Companies will exclusively work together leveraging Namaste's suppliers across the global cannabis industry and particularly those accessing Namaste's large and growing e-commerce customer base.
Oventus Medical Ltd (ASX:OVN) is pleased to provide a copy of its latest newsletter for investors.
Oventus Medical Ltd (ASX:OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.
